Current and future therapeutic options for chronic hepatitis D virus infection
In the last few years there have been innovations in HDV therapy which have brought new excitement in the scientific community also considering the few therapeutic opportunities. Recently, new molecular targets have been identified, both in monotherapy and in combination with peginterferon alpha (Pe...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Cellular and Infection Microbiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcimb.2024.1382017/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823859184948477952 |
|---|---|
| author | Mariantonietta Pisaturo Antonio Russo Pierantonio Grimaldi Salvatore Martini Nicola Coppola |
| author_facet | Mariantonietta Pisaturo Antonio Russo Pierantonio Grimaldi Salvatore Martini Nicola Coppola |
| author_sort | Mariantonietta Pisaturo |
| collection | DOAJ |
| description | In the last few years there have been innovations in HDV therapy which have brought new excitement in the scientific community also considering the few therapeutic opportunities. Recently, new molecular targets have been identified, both in monotherapy and in combination with peginterferon alpha (PegIFNα). Evaluating this review of the literature of the last ten years, HDV-related chronic hepatitis seems to have become a potentially curable disease, a statement that was unthinkable a few years ago. There are old and new weapons at our disposal. The old weapons are PegIFNα and recently PegIFN-lambda (PegIFNλ). PegIFNα, for which there are more data, appears to be an excellent combination regimen, if not contraindicated, both for Bulevirtide (BLV), data supported by important clinical trials and real-world studies, and probably for lonarfanib, although in the latter case the results are not yet definitive as the studies are fewer. However, data on long-term follow-up are needed. |
| format | Article |
| id | doaj-art-7f916f887345437fbc78d6b5e7888bf0 |
| institution | Kabale University |
| issn | 2235-2988 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cellular and Infection Microbiology |
| spelling | doaj-art-7f916f887345437fbc78d6b5e7888bf02025-02-11T06:59:37ZengFrontiers Media S.A.Frontiers in Cellular and Infection Microbiology2235-29882025-02-011410.3389/fcimb.2024.13820171382017Current and future therapeutic options for chronic hepatitis D virus infectionMariantonietta PisaturoAntonio RussoPierantonio GrimaldiSalvatore MartiniNicola CoppolaIn the last few years there have been innovations in HDV therapy which have brought new excitement in the scientific community also considering the few therapeutic opportunities. Recently, new molecular targets have been identified, both in monotherapy and in combination with peginterferon alpha (PegIFNα). Evaluating this review of the literature of the last ten years, HDV-related chronic hepatitis seems to have become a potentially curable disease, a statement that was unthinkable a few years ago. There are old and new weapons at our disposal. The old weapons are PegIFNα and recently PegIFN-lambda (PegIFNλ). PegIFNα, for which there are more data, appears to be an excellent combination regimen, if not contraindicated, both for Bulevirtide (BLV), data supported by important clinical trials and real-world studies, and probably for lonarfanib, although in the latter case the results are not yet definitive as the studies are fewer. However, data on long-term follow-up are needed.https://www.frontiersin.org/articles/10.3389/fcimb.2024.1382017/fullHDVHDV managementHDV treatmentbulevirtidelonafarnib |
| spellingShingle | Mariantonietta Pisaturo Antonio Russo Pierantonio Grimaldi Salvatore Martini Nicola Coppola Current and future therapeutic options for chronic hepatitis D virus infection Frontiers in Cellular and Infection Microbiology HDV HDV management HDV treatment bulevirtide lonafarnib |
| title | Current and future therapeutic options for chronic hepatitis D virus infection |
| title_full | Current and future therapeutic options for chronic hepatitis D virus infection |
| title_fullStr | Current and future therapeutic options for chronic hepatitis D virus infection |
| title_full_unstemmed | Current and future therapeutic options for chronic hepatitis D virus infection |
| title_short | Current and future therapeutic options for chronic hepatitis D virus infection |
| title_sort | current and future therapeutic options for chronic hepatitis d virus infection |
| topic | HDV HDV management HDV treatment bulevirtide lonafarnib |
| url | https://www.frontiersin.org/articles/10.3389/fcimb.2024.1382017/full |
| work_keys_str_mv | AT mariantoniettapisaturo currentandfuturetherapeuticoptionsforchronichepatitisdvirusinfection AT antoniorusso currentandfuturetherapeuticoptionsforchronichepatitisdvirusinfection AT pierantoniogrimaldi currentandfuturetherapeuticoptionsforchronichepatitisdvirusinfection AT salvatoremartini currentandfuturetherapeuticoptionsforchronichepatitisdvirusinfection AT nicolacoppola currentandfuturetherapeuticoptionsforchronichepatitisdvirusinfection |